Albrethsen Jakob, Møller Christian H, Olsen Jesper, Raskov Hans, Gammeltoft Steen
Department of Clinical Biochemistry, Glostrup Hospital, 2600 Glostrup, Denmark.
Eur J Cancer. 2006 Nov;42(17):3057-64. doi: 10.1016/j.ejca.2006.05.039. Epub 2006 Oct 2.
Colorectal cancer (CRC) patients have increased levels of human neutrophil peptides 1-3 (HNP1-3) in tumour tissue and plasma. The aim is to study whether the amount of HNP1-3 in tumour and plasma from CRC patients correlate with Dukes' stages A-D. The amount of HNP1-3 in tumour tissue, normal colonic mucosa, and plasma was determined with mass spectrometry. Plasma levels of HNP1-3 were determined with enzyme-linked immuno-sorbent assay (ELISA). The amount of HNP1-3 determined with mass spectrometry was increased in tumours compared to normal colonic tissue in CRC patients in Dukes' stage A-D, whereas HNP1-3 in plasma was only elevated in Dukes' stage D compared to healthy individuals. HNP1-3 plasma concentration determined with ELISA was increased in Dukes' stages C and D, but not in A and B. It is concluded that HNP1-3 is a potential marker for prognostic assessment, surveillance of patients, and monitoring chemotherapy in CRC patients with advanced disease.
结直肠癌（CRC）患者肿瘤组织和血浆中的人中性粒细胞肽1-3（HNP1-3）水平升高。目的是研究CRC患者肿瘤组织和血浆中HNP1-3的含量是否与Dukes分期A-D相关。采用质谱法测定肿瘤组织、正常结肠黏膜和血浆中HNP1-3的含量。采用酶联免疫吸附测定法（ELISA）测定血浆中HNP1-3的水平。在Dukes分期A-D的CRC患者中，与正常结肠组织相比，肿瘤中通过质谱法测定的HNP1-3含量增加，而与健康个体相比，血浆中的HNP1-3仅在Dukes分期D时升高。通过ELISA测定的HNP1-3血浆浓度在Dukes分期C和D时升高，但在A和B期未升高。结论是，HNP1-3是晚期CRC患者预后评估、患者监测和化疗监测的潜在标志物。
